Review Article
Cardiovascular and Cancer Risk: The Role of Cardio-oncology
Jessica Shank Coviello, DNP, APRN, ANP-BC
Yale School of Nursing and Smilow Cancer Hospital, New Haven, Connecticut
Author’s disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Jessica Shank Coviello, DNP, APRN, ANP-BC, Yale University School of Nursing, PO Box 27399, West Haven, CT 06516-7399 E-mail: jessica.coviello@yale.edu
J Adv Pract Oncol 2018;9(2):160–176 |
https://doi.org/10.6004/jadpro.2018.9.2.3 |
© 2018 Harborside™
ABSTRACT
Abstract
Cardio-oncology is a subspecialty of cardiology. It was created to address oncology data indicating that newly developed drugs for cancer treatment were having unanticipated cardiac side effects. Cardio-oncology designs primary and secondary risk strategies through surveillance as well as interventions to reduce cardiovascular risk (CVR), prevent cardiotoxicities, and manage the side effects that may occur. Rather than discuss in detail the cardiotoxicities of specific therapies or radiation, this review article will explore the interplay of cancer, cancer treatment, and CVR. It will examine the link between CVR and cancer risk, define mechanisms associated with cardiotoxicity, and describe screening and surveillance for patients undergoing cancer treatment. Finally, effective preventative and management strategies used to reduce the incidence of cardiotoxicities in those receiving chemotherapeutics or radiation will be presented.
For access to the full length article, please
sign in.
